Artesunate—multiple pharmacological effects beyond treating malaria

IF 5.9 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-03-15 Epub Date: 2025-01-18 DOI:10.1016/j.ejmech.2025.117292
Yuzhi Chang , Tong Lyu , Xingyue Luan , Yiming Yang , Yaming Cao , Yue Qiu , Hui Feng
{"title":"Artesunate—multiple pharmacological effects beyond treating malaria","authors":"Yuzhi Chang ,&nbsp;Tong Lyu ,&nbsp;Xingyue Luan ,&nbsp;Yiming Yang ,&nbsp;Yaming Cao ,&nbsp;Yue Qiu ,&nbsp;Hui Feng","doi":"10.1016/j.ejmech.2025.117292","DOIUrl":null,"url":null,"abstract":"<div><div>Artesunate, a semisynthetic derivative of artemisinin, is not only recommended as the first-line drug for treating severe malaria but is also a significant member of Artemisinin-based Combination Therapies (ACTs), used in combination with other artemisinin derivatives for treating uncomplicated malaria. Beyond its potent anti-malarial activity, artesunate has garnered considerable attention for its pharmacological effects, which encompass broad-spectrum anti-tumor, anti-viral, and anti-inflammatory properties. It has collectively demonstrated superior drug tolerance, low toxicity, and mild side effects in cell line experiments <em>in vitro</em>, experimental animal models, and clinical drug researches, as a monotherapy or in combination with other agents. Investigating the pharmacological effects of artesunate will facilitate the exploration of novel drug applications and enhance the comprehensive clinical applications.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"286 ","pages":"Article 117292"},"PeriodicalIF":5.9000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425000571","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Artesunate, a semisynthetic derivative of artemisinin, is not only recommended as the first-line drug for treating severe malaria but is also a significant member of Artemisinin-based Combination Therapies (ACTs), used in combination with other artemisinin derivatives for treating uncomplicated malaria. Beyond its potent anti-malarial activity, artesunate has garnered considerable attention for its pharmacological effects, which encompass broad-spectrum anti-tumor, anti-viral, and anti-inflammatory properties. It has collectively demonstrated superior drug tolerance, low toxicity, and mild side effects in cell line experiments in vitro, experimental animal models, and clinical drug researches, as a monotherapy or in combination with other agents. Investigating the pharmacological effects of artesunate will facilitate the exploration of novel drug applications and enhance the comprehensive clinical applications.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
青蒿琥酯-治疗疟疾以外的多重药理作用
青蒿琥酯是青蒿素的一种半合成衍生物,不仅被推荐作为治疗严重疟疾的一线药物,而且也是以青蒿素为基础的联合疗法(ACTs)的重要成员,与其他青蒿素衍生物联合使用,用于治疗无并发症的疟疾。除了其有效的抗疟疾活性外,青蒿琥酯还因其广谱抗肿瘤、抗病毒和抗炎特性的药理作用而引起了相当大的关注。在体外细胞系实验、实验动物模型和临床药物研究中,无论是作为单一疗法还是与其他药物联合使用,它都显示出优越的药物耐受性、低毒性和轻微的副作用。研究其对不同疾病的药理作用将促进青蒿琥酯新药应用的探索,促进其更全面的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
Design and optimization of potent, selective, and peripherally acting JNK3 inhibitors for chronic kidney disease Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia Targeting Staphylococcus aureus with potent de novo-designed proline-core short antimicrobial lipopeptides Who's who in the field of combretastatin A4 analogues: ? Mitochondria-targeted engineered peptide promotes myogenesis, mitigates fibrosis, and reduces inflammation in duchenne muscular dystrophy by suppressing mitoROS-mediated NF-κB activation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1